

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <http://orca.cf.ac.uk/109769/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Masson, Emmanuelle, Chen, Jian-Min, Cooper, David and Férec, Claude 2018. PRSS1 copy number variants and promoter polymorphisms in pancreatitis: common pathogenetic mechanism, different genetic effects. *Gut* 67 (3) , pp. 592-593. 10.1136/gutjnl-2017-314443 file

Publishers page: <http://dx.doi.org/10.1136/gutjnl-2017-314443> <<http://dx.doi.org/10.1136/gutjnl-2017-314443>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



*PRSSI* copy number variants and promoter polymorphisms in  
pancreatitis: common pathogenetic mechanism, different genetic  
effects

**Emmanuelle Masson,<sup>1,2</sup> Jian-Min Chen,<sup>1,3,4</sup> David N. Cooper,<sup>5</sup> Claude Férec,<sup>1,2,3,4</sup>**

<sup>1</sup>Institut National de la Santé et de la Recherche Médicale (INSERM), U1078, Brest, France

<sup>2</sup>Laboratoire de Génétique Moléculaire et d'Histocompatibilité, Centre Hospitalier  
Universitaire (CHU) Brest, Hôpital Morvan, Brest, France

<sup>3</sup>Etablissement Français du Sang (EFS) – Bretagne, Brest, France

<sup>4</sup>Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale  
(UBO), Brest, France

<sup>5</sup>Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United  
Kingdom

**Word count: 597**

**Abbreviations:** CNVs, copy number variants

**Keywords:** chronic pancreatitis; copy number variant; duplication; promoter variant, *PRSSI*  
gene

**Correspondence to** Dr Jian-Min Chen, INSERM U1078 and EFS – Bretagne, 46 rue Félix  
Le Dantec, 29218 Brest 29218, France; [Jian-Min.Chen@univ-brest.fr](mailto:Jian-Min.Chen@univ-brest.fr)

We have read with interest three related papers that were recently published in this journal.<sup>1-3</sup>

Taken together, the findings reported in these papers (summarized in [online supplementary note](#)) suggest that loss-of-function *PRSSI* promoter variants can protect against pancreatitis. The other side of the coin is however that gain-of-function *PRSSI* promoter variants predispose to pancreatitis. It therefore follows that the risk-associated [rs4726576C; rs10273639C] allele shares a common pathogenetic mechanism with the previously reported trypsinogen duplication and triplication copy number variants (CNVs)<sup>4,5</sup> since both types of variant predispose to pancreatitis by increasing *PRSSI* expression; this mechanism is quite distinct from either the increased activation and/or stability of trypsin(ogen) or misfolding-induced endoplasmic reticulum stress caused by disease-associated *PRSSI* missense mutations.<sup>6</sup> However, despite both serving to increase *PRSSI* expression, the promoter variant and the CNVs differ significantly in terms of the relative strength of their genetic effects. The risk-associated [rs4726576C; rs10273639C] allele (whose frequency was found to be 0.54 and 0.57 respectively in healthy French individuals of European ancestry<sup>3</sup> and controls from the North American Pancreatitis Study 2<sup>7</sup>) had only a modest genetic effect, defined as having an Odds Ratio of <1.5 in accordance with ref. 8, with respect to the clinical phenotype. By contrast, the *PRSSI* duplication/triplication CNVs, which have never been reported in normal populations, can be classified as disease-causative.

Despite their evident clinical importance, *PRSSI* CNVs have not so far been analysed by many research groups. Apart from the technical difficulties inherent in detecting CNVs, particularly those characterized by an increased copy number, there may be another reason viz. the *PRSSI* duplication and triplication CNVs found in French Caucasian patients with hereditary, familial or sporadic chronic pancreatitis<sup>4,5</sup> arose from a common founder chromosome.<sup>9</sup> However, a *PRSSI* CNV was also identified in one of 75 Chinese children with idiopathic chronic pancreatitis.<sup>10</sup> Although the breakpoints of this CNV have not yet

been characterized, the Chinese data provided the first evidence that pathogenic *PRSSI* CNVs have more than one independent origin. Indeed, during our routine screening of young French patients with chronic pancreatitis or acute recurrent pancreatitis (see methods in [online supplementary note](#)), we identified and characterized four novel and non-identical *PRSSI* duplication CNVs ([figure 1](#)): #2 in a Caucasian patient with a family history of the disease; #3 in a *Maghrebian* patient with sporadic pancreatitis; #4 in a Caucasian patient plus two family members (brother and father); and #5 in a sporadic pancreatitis patient from *French Guiana*. Not surprisingly, all four novel duplication CNVs involved the entire *PRSSI* gene, as well as the entire anionic trypsinogen (*PRSS2*) gene.

In summary, the recent publications on common *PRSSI* promoter variants<sup>1-3</sup> and the ongoing discovery of rare *PRSSI* CNVs serve to emphasize the key role of increased *PRSSI* expression in the aetiology of pancreatitis. Our new findings demonstrating multiple independent origins for *PRSSI* CNVs, taken together with the earlier Chinese findings<sup>10</sup>, suggest that, irrespective of their ethnogeographic origin, *PRSSI* CNVs could be present in those pancreatitis patients in whom a genetic risk factor has not yet been identified. Routine screening for this important type of disease-causing variant is therefore warranted in pancreatitis.

**Contributors** EM, JMC and CF designed the study. EM performed the analysis. JMC drafted the manuscript. DNC critically revised the manuscript. All authors analysed the data and approved the final manuscript.

**Funding** Support for this study came from the Association des Pancréatites Chroniques Hérititaires, the Association de Transfusion Sanguine et de Biogénétique Gaetan Saleun, and the Institut National de la Santé et de la Recherche Médicale (INSERM), France.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** Ethical Committee of the University of Brest.

## REFERENCES

- 1 Derikx MH, Kovacs P, Scholz M, *et al.* Polymorphisms at *PRSSI-PRSS2* and *CLDN2-MORC4* loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study. *Gut* 2015;64:1426-33.
- 2 Masamune A, Nakano E, Hamada S, *et al.* Common variants at *PRSSI-PRSS2* and *CLDN2-MORC4* loci associate with chronic pancreatitis in Japan. *Gut* 2015;64:1345-6.
- 3 Boulling A, Sato M, Masson E, *et al.* Identification of a functional *PRSSI* promoter variant in linkage disequilibrium with the chronic pancreatitis-protecting rs10273639. *Gut* 2015;64:1837-8.
- 4 **Missing reference?** Le Maréchal C, Masson E, Chen JM, *et al.* Hereditary pancreatitis caused by triplication of the trypsinogen locus. *Nat Genet* 2006;38:1372-4.
- 5 Masson E, Le Maréchal C, Chandak GR, *et al.* Trypsinogen copy number mutations in patients with idiopathic chronic pancreatitis. *Clin Gastroenterol Hepatol* 2008;6:82-8.
- 6 Schnúr A, Beer S, Witt H, *et al.* Functional effects of 13 rare *PRSSI* variants presumed to cause chronic pancreatitis. *Gut* 2014;63:337-43.
- 7 Whitcomb DC, LaRusch J, Krasinskas AM, *et al.* Common genetic variants in the *CLDN2* and *PRSSI-PRSS2* loci alter risk for alcohol-related and sporadic pancreatitis. *Nat Genet* 2012;44:1349-54.
- 8 Manolio TA, Collins FS, Cox NJ, *et al.* Finding the missing heritability of complex diseases. *Nature* 2009;461:747-53.
- 9 Chauvin A, Chen JM, Quemener S, *et al.* Elucidation of the complex structure and origin of the human trypsinogen locus triplication. *Hum Mol Genet* 2009;18:3605-14.
- 10 Wang W, Sun XT, Weng XL, *et al.* Comprehensive screening for *PRSSI*, *SPINK1*, *CFTR*, *CTRC* and *CLDN2* gene mutations in Chinese paediatric patients with idiopathic chronic pancreatitis: a cohort study. *BMJ Open* 2013;3:e003150.

## Figure legend

**Figure 1** Schematic illustration of the *PRSSI* (as well as *PRSS2*) duplication CNVs whose breakpoints have been characterized at the nucleotide sequence level. The start and end positions of each duplicated segment are indicated in accordance with human GRCh38/hg38. The critical region contained within these duplicated sequences is indicated by vertical dotted lines. Whereas #3, #4 and #5 are simple duplications, #1 and #2 are complex duplications. In #1, only the functionally relevant duplicated segment is shown; this duplicated allele gave rise to the previously known triplication allele.<sup>9</sup> In #2, an insertion was present in the aberrant chromosomal junction. Sequences spanning the aberrant chromosomal junctions of the four novel *PRSSI* duplication CNVs are provided in [supplementary figure S1](#).